Indogulf Cropsciences Limited (MAINBOARD)
June 26, 2025 – June 30, 2025
| Price | ₹105 - ₹111 |
| Premium | ₹18 |
|---|---|
| Lot size | 135 |
| Allotment | Jul 1, 2025 |
| Listing | Jul 3, 2025 |
Live Rate
| Open | |
|---|---|
| High | |
| Low | |
| Prev. Close | |
| Lower circuit | |
| Upper circuit | |
| 52w High | |
| 52w Low | |
| P/E Ratio |
Listing Price
| Exchange | Listing Price | Gain/Loss | % |
|---|---|---|---|
| NSE | ₹111.00 | ₹0.00 | 0.00% |
| BSE | ₹111.00 | ₹0.00 | 0.00% |
Subscription
Last updated on 30-Jun-2025 18:32:08
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIBs | 3495496 | 119479455 | 34.18 |
| HNIs | 2621622 | 132608745 | 50.58 |
| HNIs 10+ | 1747748 | 93928140 | 53.74 |
| HNIs 2+ | 873874 | 38680605 | 44.26 |
| Retail | 6117117 | 94484880 | 15.45 |
| Employees | 600000 | 693225 | 1.16 |
| Total | 12834235 | 347266305 | 27.06 |
Application-Wise Breakup (Approx. no. of Apps) | |||
|---|---|---|---|
| Category | Reserved | Applied | Times |
| HNIs (10L+) | 925 | 10199 | 11.03 |
| HNIs (2-10L) | 462 | 19884 | 43.04 |
| Retail | 45312 | 617280 | 13.62 |
| Employee | - | 2972 | - |
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIBs | 38.8 | 1326.22 | 34.18 |
| FIIs | - | 32.73 | - |
| DIIs | - | 932.28 | - |
| Mutual funds | - | 0 | - |
| Others | - | 361.21 | - |
| HNIs | 29.1 | 1471.96 | 50.58 |
| HNIs 10+ | 19.4 | 1042.6 | 53.74 |
| HNIs 2+ | 9.7 | 429.35 | 44.26 |
| Retail | 67.9 | 1048.78 | 15.45 |
| Employees | 6.66 | 7.69 | 1.16 |
| Total | 142.46 | 3854.66 | 27.06 |
| QIB Interest Cost per share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹5.1 | @8% ₹5.8 | @9% ₹6.5 | @10% ₹7.3 | @11% ₹8 | @12% ₹8.7 |
About
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 135 | 14985 | 45312 |
| sHNI | 14 | 1890 | 209790 | 462 |
| bHNI | 67 | 9045 | 1003995 | 925 |
IPO Details
| Total Issue Size | 1,80,18,017 shares (aggregating up to 200 Cr) |
| Fresh Issue | 1,44,14,414 shares (aggregating up to 160 Cr) |
| Offer for Sale | 36,03,603 shares (aggregating up to 40 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 4,87,87,456 shares |
| Share Holding Post Issue | 6,32,01,870 shares |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Offer |
| Retail Shares Offered | Not less than 35% of the Offer |
| NII (HNI) Shares Offered | Not less than 15% of the Offer |
Key Performance Indicator (KPI)
| KPI | Dec-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 8.17% | 12.19% | 11.03% |
| ROCE | 8.07% | 11.93% | 10.12% |
| RONW | 8.17% | 12.19% | 11.03% |
| EPS (basic) | 5.1 | 12 | 9.53 |
| P/E Pre IPO | 19.18 | ||
| P/E Post IPO | 24.27 |
Company Financials In Crores
| Period Ended | Dec-24 | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|---|
| Assets | 597.81 | 542.25 | 517.51 | 413.59 |
| Revenue | 466.31 | 555.79 | 552.19 | 490.23 |
| Profit After Tax | 21.68 | 28.23 | 22.42 | 26.36 |
| EBITDA | 44.78 | 55.74 | 49.04 | 47.24 |
| Net Worth | 265.43 | 231.65 | 203.25 | 180.51 |
| Reserves and Surplus | 216.64 | 208.01 | 179.6 | 156.87 |
| Total Borrowing | 206.3 | 154.56 | 189.22 | 101.38 |
Company Overview
Incorporated: 1993
Business: Manufacturing of crop protection products, plant nutrients, and biologicals
Notable Products:
Spiromesifen technical (96.5% purity, since 2019)
Among the first in India to manufacture Pyrazosulfuron Ethyl technical (97% purity)
Manufacturing Facilities:
4 units across ~20 acres in Samba (J&K) and Nathupur & Barwasni (Haryana)
Sales Network:
India: 22 states + 3 Union Territories
Global: 129 partners in 34 countries
Strength
Wide Domestic and Global Distribution Network: The company has a strong sales presence across 22 Indian states and 3 Union Territories, supported by over 5,700 distributors and 169 business partners, along with international reach in 34 countries.
Backward-Integrated Manufacturing Facilities: Indogulf’s in-house, multi-purpose production units across Jammu & Kashmir and Haryana ensure better control over quality, cost, and supply chain efficiency.
Robust R&D and Innovation Capabilities: The company demonstrates strong technical leadership, with a track record of pioneering products like Spiromesifen and Pyrazosulfuron Ethyl, supported by ongoing research and product development.
Weakness
Risk of Quality Control Failures: The company’s success relies heavily on strict adherence to quality standards. Any lapses could lead to order cancellations, loss of customer trust, or warranty claims, directly impacting revenue and reputation.
Brand Reputation Vulnerability: Negative publicity, product issues, or changes in branding could weaken brand value and customer perception, potentially affecting market share and financial performance.
Underutilization of Manufacturing Capacity: Inability to fully utilize existing or expanded production facilities may lead to increased costs and reduced profitability, posing challenges to long-term business growth.
Latest Announcements
| Date | Subject | Attachment Text |
|---|
Financial Results
Lead Manager(s)
Address
Plot No - D-9,
Netaji Subhash Place
Delhi, New Delhi, 110034
Phone: +91 11 4004 0417
Email: cs@groupindogulf.com
Website: http://www.groupindogulf.com/